// App-Quantinova.ai

: Population pharmacokinetic (PK) analysis of fluticasone furoate (FF)/umeclidimium (UMEC)/vilanterol (VI) via a single inhaler in patients with COPD (FULFIL)

Researchers

Presenter

  • Rashmi Mehta

Principal Investigators

  • Eleni Pefani

  • Misba Beerahee

  • Helen Barnacle

  • Ruby Birk

  • Noushin Brealey

  • Chang-Qing Zhu

  • David A. Lipson

Medical Centers

  • NIH/NIEHS, Research Triangle Park, United States of America

  • GSK, Stevenage, Hertfordshire, United Kingdom

  • GSK, Stockley Park West, Uxbridge, Middlesex, United Kingdom,

  • GSK, King of Prussia, PA, United States of America

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Fluticasone furoate

  • Umeclidinium

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved